Prime: Studies, Joseph | Training | Training

Hello attached please find t	Helia standard please find to 30 Day pricing for Geora. Please confirm that you have recoded this error.														
Product Name	NDC	DRUG PROD DESC	INTRODUCED TO MARKET DATE	WAC AT INTRODUCTION	MARKETING PRICING PLAN	MARKETING PRICING NONPUBLIC	ESTIMATED PATIENTS	BREAKTHROUGH THERAPY INDICATOR	PRIORITY REVIEW INDICATOR	ACQUISITION DATE	ACQUISITION PRICE	ACQUISITION PRICE NONPUBLIC	ACQUISITION PRICE COMMENT	GENERAL COMMENTS	
							[The estimated number								
							of patients in the United								
							States with a condition								
							for which the new								
							prescription drug may be prescribed.1								
		BEOVUE	10.8.2019	\$1,850			700.000	No						There are 700,000 patients with	
(brolucinamab-dbli)	0078-	(brolucizumab-dbll) is	10.8.2019	\$1,850	Novertis considered many factors in determining the price	N/A	700,000	No	Yes	N/A	NA	NIA	N/A	There are 700,000 patients with wAMD in the US for whom Beovulb	
(brolucizumao-doli)	0627-61	a human yasqular			of Begyulii. We believe Begyu									may be prescribed however, it is	
		a numan vascuar endothelial growth			is poised to substantially									may be prescribed; nowever, it is most likely only 53,000 US patients	
		factor (VEGF)			reduce the burden of									may potentially be prescribed	
		inhibitor indicated for			Neovascular (Wet) Age-									Beovult in	
		the treatment of			Related Macular Degeneration									2020.	
		Neovascular (Wet)			(AMD) on patients, caregivers,									We believe that all information	
		Age-Related Macular			insurers, the US healthcare									submitted by Novartis to the	
		Degeneration (AMD).			system and society as a whole.									Department of Vermont Health	
		BEOVUB is			With our pricing methodology,									Access or to the Attorney General	
		administered by			we are focused on access to									under Vt. Stat. tit. 18 55 4635 or 4637,	
		injection and			BECVUB for this patient population.									including all information contained in	
		available by			population.									this aubmission, is confidential and	
		prescription only.												proprietary commercial or financial information not subject to disclosure.	
		SECVUB injection is												including under the Vermont Public	
		a sterile.												Records Act (Subchapter 3 of Chapter	
		preservative-free.												5 of the Vermont Statutes) and	
		clear to slightly												applicable laws pertaining to trade	
		opalescent, colorless												secrets. We request that the	
		to slightly brownish-												confidentiality of this submission and	
		yellow solution in a												of all Novartis' related information	
		single-dose vial for												herein be maintained to the maximum	
		intravitreal												extent permitted by law. To the extent	
		administration. Each vial is designed to												that any of this designated information	
		vial is designed to deliver 0.05 mL of												is requested, whether under Vermont Public Records Act (Subchapter 3 of	
		solution containing 6												Chapter 5 of the Vermont Statutes) or	
1	1	ma brolucizumab-		ı	l	1	1	I	l		1	I	l	otherwise, we request that Novertis	
1	1	dbill, polysorbate 80		l	l	1	1	l	I	1	l	I	I	be notified of the request and afford	
1	1	(0.02%), sodium		ı	l	1	1	I	l		1	I	l	us the coportunity to submit	
1	1	citrate (10 mM),		l	l	1	1	l	I	1	l	I	I	objections to disclosure.	
1		sucrose (5.8%), and		ı	l	1	1	I	l		1	I	l	1 -	
1	1	Water for Injection,		ı	l	1	1	I	l		1	I	l	1	
		USP and with a pH of													
	1	approximately 7.2.													

James Mackey
Associals Director, Government Pricing
Phone +1 802 2004 4056
james answerightecomis com
Managed Marketin FinanciaNCA
Novel Managed Marketin FinanciaNCA
Novel Managed Marketin FinanciaNCA
Solve Managed Man